These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26317252)

  • 21. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for cholesterol hyperabsorbers and hyperproducers based on comparative low-density lipoprotein reductions achieved by ezetimibe versus statins.
    Senaratne J; Griffiths J; MacDonald K; Senaratne MP
    J Cardiopulm Rehabil Prev; 2012; 32(5):250-4. PubMed ID: 22785146
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [LDL-Cholesterol--Is there an "LDL hypothesis"?].
    Custodis F; Laufs U
    Dtsch Med Wochenschr; 2015 May; 140(10):761-4. PubMed ID: 25970418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
    Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
    Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing to low-density lipoprotein particles compared with low-density lipoprotein cholesterol: a cost-effectiveness analysis.
    Rizzo JA; Mallow PJ; Waters HC; Pokrywka GS
    J Clin Lipidol; 2013; 7(6):642-52. PubMed ID: 24314363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is There a Need to Revise Goals in the Management of Dyslipidemias?
    Sinning D; Landmesser U
    Curr Cardiol Rep; 2019 Apr; 21(6):51. PubMed ID: 31041621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?].
    Vaverková H
    Vnitr Lek; 2007 Apr; 53(4):421-7. PubMed ID: 17578178
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of low-density lipoprotein targets.
    Whayne TF
    Angiology; 2013 Aug; 64(6):411-6. PubMed ID: 22734087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial.
    Pearson TA; Denke MA; McBride PE; Battisti WP; Brady WE; Palmisano J
    Mayo Clin Proc; 2005 May; 80(5):587-95. PubMed ID: 15887425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
    Ballantyne CM; Hoogeveen RC; Raya JL; Cain VA; Palmer MK; Karlson BW;
    Atherosclerosis; 2014 Jan; 232(1):86-93. PubMed ID: 24401221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis.
    Kinlay S
    J Am Coll Cardiol; 2007 May; 49(20):2003-9. PubMed ID: 17512355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of ezetimibe on LDL-cholesterol: quantitative or qualitative changes?
    Rizzo M; Rini GB; Spinas GA; Berneis K
    Atherosclerosis; 2009 Jun; 204(2):330-3. PubMed ID: 19027905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials.
    Morrone D; Weintraub WS; Toth PP; Hanson ME; Lowe RS; Lin J; Shah AK; Tershakovec AM
    Atherosclerosis; 2012 Aug; 223(2):251-61. PubMed ID: 22410123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [State of the Art: Statin Therapy].
    Laufs U; Weingärtner O; Kassner U; Schatz U
    Dtsch Med Wochenschr; 2022 Jan; 147(1-02):62-68. PubMed ID: 34872149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of baseline low-density lipoprotein cholesterol values on statin therapy persistence.
    Citarella A; Linder M; Kieler H; Berglind IA; Sundström A; Wettermark B; Andersen M
    Eur J Clin Pharmacol; 2016 Mar; 72(3):349-57. PubMed ID: 26671240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.